What business models work in the alternative protein market?

What does an alternative protein business model need to prove before we can say it works?

In alternative protein today, a business model works when repeat demand, healthy gross profit and sensible capital requirements show up at the same time.

That sounds obvious, but the sector spent years treating other milestones as proof of commercial success. A regulatory approval proves that a cultivated product can legally reach consumers. A supermarket listing proves that a retailer is willing to test it. A large funding round proves that investors were willing to finance the company. None of those tells us whether customers will keep buying enough product at a price that leaves money after manufacturing.

So the bar for calling a business model “working” has to be fairly strict. A consumer business should show repeat purchasing and either positive unit economics or a credible path toward them. A B2B ingredient company should show customers moving beyond samples and pilots into repeat commercial orders. A manufacturing company needs enough contracted demand to keep expensive fermentation or cell-culture capacity busy. The amount of capital needed to reach those milestones matters just as much as revenue.

The distinction is more useful now because financing conditions have tightened sharply. GFI estimates that the sector raised $359 million in the first half of 2026, after raising $881 million during all of 2025. Companies can no longer assume that another large funding round will arrive before the economics work.

What we test	A business that works	A business that still needs proving
Demand	Customers repeatedly buy	Lots of trials, weak repeat buying
Economics	Meaningful gross profit	Revenue barely covers production
Manufacturing	Capacity follows visible demand	Capacity is built far ahead of sales
Scaling	Economics improve with volume	Losses remain huge as volume grows
Capital	Growth can eventually fund more growth	Constant fundraising is needed to survive

Is plant-based meat still a good business today?

Plant-based meat is still a real food category, but the premium mass-market imitation-meat model is currently a weak business.

The latest U.S. retail numbers make that fairly hard to dispute. According to SPINS data analyzed by GFI, plant-based meat and seafood sales fell 10% in dollars and 11% in units in 2025. Household penetration fell to 11%, compared with roughly 20% at its 2021 peak. Distribution also dropped about 8% in both mainstream multi-outlet stores and the natural channel.

There is one important nuance: people who still buy plant-based meat have not disappeared. About 62% of purchasing households bought it more than once, and buyers averaged roughly six shopping occasions during the year. The category has kept a core customer base while losing many occasional buyers.

That creates an awkward business model for specialist brands. A company can have millions of loyal consumers and still struggle if its factory, marketing organization and valuation were built around the assumption that tens of millions more would quickly arrive.

Beyond Meat shows what this looks like at company level. In its latest quarterly results, revenue was $68.8 million, down 8.2% year over year. Gross margin was only 8.5%, while adjusted EBITDA was negative $27.7 million. In other words, the company lost roughly 40 cents of adjusted EBITDA for every dollar of sales during the quarter.

There are pockets that behave better. Shreds, chunks and strips increased U.S. retail unit sales by 8% in 2025, and some flavored formats gained distribution. Plant-based pork also held up better than several other analog categories in foodservice. So saying that plant-based meat itself has failed would go too far.

What has failed so far is the assumption that a premium-priced imitation burger or sausage can become a huge mainstream category simply because consumers say they are interested in eating less meat. Interest and purchase frequency turned out to be very different things.

If you want more recent data on this point, please see our latest alternative protein market report.

Why does plant-based milk work so much better than plant-based meat?

Plant-based milk is currently the clearest proof that an alternative protein category can become a normal part of how millions of people eat.

The gap with plant-based meat is enormous. Plant-based milk generated around $2.7 billion of U.S. retail sales in 2025 and represented 13% of total milk sales by value. About 38% of households bought it, and 75% of those buyers purchased it more than once.

Plant-based meat reached only about 0.7% of the entire meat category when random-weight meat is included. Its household penetration was 11%. Plant-based milk therefore has roughly three and a half times the household penetration and close to 19 times the category share.

The difference partly comes from the occasion itself. Putting oat milk into coffee or cereal asks very little of the consumer. The meal remains the same. A meat substitute is often the center of the plate, so differences in taste, texture and price become much harder to ignore.

The latest Oatly numbers show that this consumer habit can support much more conventional food-company economics. Oatly's latest quarter produced $240.1 million of revenue, up 15.2% year over year. Gross margin reached 33.9%, and adjusted EBITDA was slightly positive. Europe & International revenue grew strongly, helped by particularly strong Barista product volumes.

Plant-based milk is hardly booming everywhere. U.S. retail units still fell 5% in 2025. Yet a mature category can shrink modestly for a year and remain commercially powerful. What separates plant-based milk from plant-based meat today is the size and frequency of the underlying habit.

U.S. metric	Plant-based milk	Plant-based meat and seafood
Retail sales	~$2.7B	~$1.0B
Share of conventional category	13%	~0.7% including random-weight meat
Household penetration	38%	11%
Repeat purchasers	75%	62%
Latest annual unit change	-5%	-11%

Are tofu, tempeh and mycoprotein actually better businesses than high-tech meat substitutes?

Simpler plant proteins and established fermentation products currently look more durable than many heavily engineered meat substitutes, even if they make much less exciting startup stories.

U.S. foodservice data give us a useful comparison. Analog plant-based meat accounted for 54% of plant-based protein pounds sold through the broadline distributors tracked by Circana in 2025, but its volume fell 11%. Tofu and tempeh represented more than one-third of the category and stayed roughly flat. Grain-, nut- and vegetable-based proteins increased volume by 6%.

The consumer proposition is easier. Nobody buys tofu expecting it to be indistinguishable from chicken. Tofu can succeed because people like tofu. A highly engineered chicken substitute has to clear a much tougher hurdle: it needs to resemble chicken closely enough that the consumer accepts the substitution, often while costing more.

Quorn gives us an even better long-term test because mycoprotein has been commercial for decades. Marlow Foods, which owns Quorn, reported that its latest full-year sales declined only about 1%, a big improvement from the 9% fall the year before. Quorn gained 0.9 percentage points of U.K. market share to reach 31%. Its underlying operating loss was cut from £12 million to £6 million, and the business remained cash positive at the operating level.

Quorn's current financial performance is not strong yet. The interesting part is that the company is managing a mature food-business problem: adjusting costs and products to a difficult category. It is no longer trying to prove that consumers will eat fungal protein.

That consumer-expectation gap is underrated. Alternative proteins become easier to sell when the consumer likes the product for what it is instead of constantly comparing it with an animal product that already works extremely well.

What actually makes people keep buying alternative protein?

Alternative protein sells best today when taste, convenience and nutrition are obvious and the price penalty feels reasonable; sustainability helps, but it rarely closes the sale by itself.

A recent Morning Consult survey commissioned by GFI asked more than 3,500 U.S. adults what would convince them to buy a new plant-based meat dish at a restaurant. The most selected answer was appealing flavors and ingredients at 46%. Meat-like taste and texture came next at 40%, followed by high protein at 35%. Heart-health benefits reached 29%. Environmental benefits came much lower at 21%.

The order is revealing. Consumers may care about climate or animal welfare, but dinner still has to taste good. Protein and health give the product another practical reason to exist. Environmental positioning works better as reinforcement once those basics are already convincing.

Price remains brutal in several categories. GFI's latest retail analysis found that many plant-based products still cost more than twice as much as their conventional equivalents when compared per pound, gallon or dozen. Plant-based meat varies more by type, but many formats still cost one to three times more than conventional alternatives.

Foodservice shows the same pattern. Plant-based protein volume through broadline distributors fell 5% in 2025, yet plant-based milk volume jumped 14%. Plant-based creamer already represents 28% of foodservice creamer pounds. Coffee chains have also been removing plant-based milk surcharges, making the switch easier for customers.

Health deserves more attention than it received during the first wave of plant-based marketing. Separate GFI research found that consumers who strongly agree that health is their most important food consideration spend 56% more on plant-based meat annually than consumers who disagree. Products emphasizing shorter ingredient lists, lower saturated fat or clear protein benefits were also among the areas that performed better recently.

The practical hierarchy is pretty clear: make it tasty, easy to use, nutritionally credible and reasonably priced. Sustainability can then make a good purchase feel even better.

Should alternative protein startups build their own factories?

Most alternative protein startups should currently avoid owning large factories until customer demand is far more predictable than it was during the industry's first investment boom.

The reason is simple: a fermentation tank or food plant costs money even when it is half empty. When volumes disappoint, depreciation, labor, utilities and maintenance get spread over fewer kilograms of product. What looked like vertical integration becomes expensive idle capacity.

Oatly learned this after an aggressive manufacturing expansion. The company eventually closed its Singapore plant, abandoned construction of another facility in China and pushed its supply chain toward a more asset-light structure. Management explicitly said the changes were designed to improve utilization, reduce future capital expenditure and lower costs. Its latest gross margin of 33.9% is a long way from the low-margin economics the company was producing earlier in the decade.

Meati offers a harsher example. Its former operating company raised roughly $450 million while building dedicated mycelium production infrastructure, but eventually went through a distressed restructuring and asset sale after demand and financing failed to support the original scale.

There is another way to scale. EVERY recently quadrupled its available production capacity through Huvepharma rather than constructing an equivalent fermentation network itself. Huvepharma's Biovet operation already has more than nine million liters of installed fermentation capacity.

That arrangement gives EVERY access to industrial scale while leaving much of the fixed manufacturing base with a partner that already knows how to run fermentation plants.

Owning production can eventually make sense when a process is exceptionally proprietary, capacity is unavailable elsewhere or volumes are predictable enough to keep the equipment busy. Building a giant plant mainly because the company raised enough money to do it has lately looked like one of the fastest ways to turn a promising technology into a financing problem.

Approach	Example	What happened	What we learn
Heavy owned capacity	Meati	Large capital base followed by distressed restructuring	Demand needs to arrive before the factory
Move toward asset-light	Oatly	Plants closed or cancelled while margins improved	Utilization can matter more than full control
Partner manufacturing	EVERY + Huvepharma	Capacity quadrupled using existing fermentation assets	Startups can scale without funding every tank
Dedicated CDMO	Liberation Bioindustries	600,000 L plant with more than half of nameplate capacity contracted or in late-stage agreements	Dedicated capacity looks safer when demand is visible first

If you want more recent data on this point, please see our latest alternative protein market report.

Is selling alternative protein ingredients B2B better than building another consumer brand?

For many alternative protein startups today, selling a differentiated ingredient to existing food companies looks better than trying to build an entirely new consumer brand.

The biggest advantage is that the startup can specialize. It develops an egg protein, whey protein, fat, flavor system or fermentation process while somebody else handles supermarket relationships, advertising, packaging and much of the consumer education.

EVERY is one of the strongest recent examples. Its precision-fermented egg protein is now being used across retail and foodservice products, including products reaching major U.S. retailers. In the first four months of 2026, the company said the annual orders it had secured were worth 550% of its entire 2025 order volume. The company subsequently quadrupled manufacturing capacity with Huvepharma.

Those figures are company-reported, so strong order growth should not be confused with proven profitability. They do show movement beyond the pilot stage, which is the commercial milestone we care about.

Perfect Day has followed the same broad architecture with fermentation-derived whey. Its technology has appeared in products or partnerships involving large food groups such as Nestlé, Mars, Bel and Unilever. The startup does not need every consumer to recognize the Perfect Day name for the protein to generate value.

This model also changes what the startup must defend. A consumer brand can lose shelf space surprisingly quickly. A proprietary ingredient that solves a difficult formulation problem can become embedded in several customers' products and manufacturing processes.

There is still a catch. B2B food ingredients can be a tough market with sophisticated buyers and aggressive price negotiations. A startup therefore needs genuine functionality or unusually attractive economics. Simply making the same protein through a more fashionable technology will not create much pricing power.

Is precision fermentation the best next-generation alternative protein business model right now?

Precision fermentation currently has the strongest commercial setup among the newer alternative protein technologies, particularly when companies sell high-value ingredients rather than cheap bulk protein.

Investors seem to be reaching a similar conclusion. GFI's latest industry work shows that fermentation companies raised $357 million in 2025. Cultivated meat companies raised only $73.9 million. More revealingly, the three largest fermentation financings that year went to EVERY, Formo and The Protein Brewery, and all three were tied closely to commercialization or market rollout.

The technology has one major advantage over cultivated meat: a company can make one valuable molecule instead of recreating an entire piece of animal tissue. That lets precision-fermentation companies start with proteins where a relatively small quantity does a valuable job.

Commercial manufacturing infrastructure is also starting to catch up. Liberation Bioindustries is bringing a 600,000-liter precision-fermentation facility toward operation in Indiana. The company says more than half of the plant's nameplate capacity is already under contract or in late-stage agreements, including commercial production of Vivici's beta-lactoglobulin protein. ScaleUp Bio is building a similar CDMO position in Asia with backing from ADM and Singapore-linked investors.

Cost remains the uncomfortable part. Fermentation-derived proteins still have to pay for feedstock, fermentation, downstream processing, energy and capital equipment. Commodity animal and plant proteins are produced through extraordinarily mature supply chains, so competing with them kilogram for kilogram is difficult.

The conclusion is fairly specific. Precision fermentation looks good today when the molecule is worth substantially more than its raw protein content. The case becomes much weaker when the business plan assumes fermentation will soon produce generic protein more cheaply than soy, milk or commodity meat.

If you want more recent data on this point, please see our latest alternative protein market report.

Which precision-fermented proteins have the best chance of making money?

Precision-fermented proteins have the best economics today when a small amount of protein delivers expensive functionality, especially in nutrition, texture, binding, foaming or formulation.

Egg proteins are a good example because food manufacturers use egg whites for much more than protein content. They foam, gel and bind. EVERY can therefore sell a fermentation-derived egg protein against the performance of conventional egg ingredients rather than competing purely on cost per gram of protein.

Beta-lactoglobulin has similar advantages. The dairy protein is useful in sports nutrition and high-protein formulations because of its amino-acid profile and physical properties. Vivici is targeting products such as clear protein drinks, protein powders and bars, with Liberation Bioindustries supplying commercial-scale fermentation.

Whey proteins from companies such as Perfect Day fit the same pattern. Ice cream, sports nutrition and formulated foods can support much higher ingredient prices than commodity flour or animal feed.

The weakest place to begin is bulk protein. If the customer mainly wants inexpensive grams of protein, fermentation has to fight mature soy, pea, dairy and animal supply chains on their strongest ground.

We could eventually see fermentation costs fall enough to attack much larger commodity markets. For now, the better business is usually to manufacture something that is difficult to replace rather than simply manufacture a lot of protein.

Can cultivated meat actually make money from selling meat today?

Cultivated meat can now be sold in several markets, but we still do not have evidence that selling cultivated meat at meaningful scale is a durable standalone business.

The regulatory progress is real. Companies including UPSIDE Foods, GOOD Meat, Vow, Wildtype, Mission Barns, Believer Meats and PARIMA have received clearances in markets including the United States, Singapore and Australia. Wildtype has served cultivated salmon in U.S. restaurants, while Mission Barns became the first company to sell a cultivated-meat product through a U.S. grocery store when its pork-fat meatballs reached Berkeley Bowl on a limited basis.

Commercial scale tells a very different story. GFI counted only $73.9 million of investment into cultivated-meat companies during 2025. The three largest rounds, Aleph Farms at $29 million, Mosa Meat at $17.6 million and BlueNalu at roughly $11 million, represented close to four-fifths of the entire year's financing.

At the same time, several serious companies ran out of runway. Meatable ceased operations after failing to secure enough new financing. Believer Meats also shut down after building a North Carolina facility designed for up to 12,000 tonnes of annual cultivated-chicken production and receiving U.S. regulatory approval.

That combination is hard to ignore. The sector is achieving more regulatory approvals while attracting much less private capital than during the earlier boom. The financing market is clearly responding more to economics now than to the novelty of an approval.

Cultivated meat may still reach mass-market economics later. We simply cannot point to a producer today and show large recurring meat sales, attractive margins and a factory operating near enough to capacity to validate the original vertically integrated model.

If you want more recent data on this point, please see our latest alternative protein market report.

Are hybrid products the smartest way to sell cultivated meat?

Hybrid products currently look like the most practical route for cultivated meat because they use expensive animal cells only where those cells add a lot of taste or texture.

Mission Barns illustrates the idea clearly. Its commercial meatballs combine plant protein with cultivated pork fat. The company is concentrating cell-culture technology on fat because fat contributes heavily to aroma, juiciness and mouthfeel.

That can radically change the manufacturing requirement. A company selling a burger made entirely from cultured cells needs enough cell-culture output for essentially the whole product. A hybrid company may need only a fraction of that volume for each kilogram sold.

GOOD Meat has already taken the same idea quite far in Singapore. One retail product contained only 3% cultivated meat, with the rest coming from plant-based ingredients. Purists may argue that this weakens the promise of fully cultivated meat, but the business logic is easy to understand: every percentage point replaced with a cheaper ingredient lowers the amount that needs to come out of a bioreactor.

The most sensible early markets may therefore look quite different from the original vision of cultured steaks replacing conventional steaks one-for-one. Cultivated fat, hybrid meatballs, premium seafood and small amounts of cell-derived material inside higher-value foods all demand far less manufacturing volume.

We still need commercial sales data before calling hybrid cultivated meat proven. But hybrids attack the sector's cost problem directly instead of waiting for a giant future factory to make it disappear.

Can alternative protein suppliers make money even if the big consumer brands fail?

Some of the best alternative protein businesses may end up selling manufacturing capacity, proteins, strains or process technology to other companies rather than selling burgers or milk to consumers.

The CDMO model is starting to become especially interesting in fermentation. ScaleUp Bio operates as a precision-fermentation contract development and manufacturing organization in Singapore, helping customers move from development into pilot and commercial production. Liberation Bioindustries is taking the concept to much larger scale with its 600,000-liter Indiana facility.

The smartest version of this model goes beyond alternative protein. Liberation plans to serve food, chemicals and other industrial products. That gives its fermentation assets more possible customers and reduces dependence on whether one food category grows fast enough.

Equipment and process technology can create similar economics in cultivated meat. Cell lines, media, bioreactor designs, sensors and process-control technology can potentially be sold to several producers. A supplier does not have to predict which cultivated chicken or salmon brand eventually wins.

There is also evidence that alternative-protein technology can make money in adjacent markets before the food application reaches scale. IntegriCulture in Japan has developed revenue from research tools and other cell-culture applications alongside its food work.

The obvious risk is that picks-and-shovels businesses need enough miners. A fermentation CDMO with empty tanks is still a bad business. The recent disclosure from Liberation that more than half of its first plant's capacity is contracted or in late-stage agreements is therefore much more meaningful than simply announcing the size of the facility.

Do big food companies have an advantage over alternative protein startups now?

Big food and ingredient companies currently have a major advantage in manufacturing and distribution, which makes partnership increasingly attractive for alternative protein startups with genuinely differentiated technology.

A startup entering food has to solve several difficult problems at once. It needs a good product, regulatory compliance, reliable manufacturing, ingredient procurement, packaging, retailer relationships, working capital and consumer acquisition. Nestlé, Danone, ADM or a large dairy group already has most of that infrastructure.

Recent deals show the two sides increasingly dividing the work. ADM is a shareholder in ScaleUp Bio. Danone has invested in precision-fermentation dairy company Imagindairy. Perfect Day has worked with several established food companies. EVERY is manufacturing with Huvepharma rather than recreating a huge fermentation footprint internally.

This does not mean every alternative protein startup should become a licensing company. Consumer brands can still own valuable relationships and margins when the category works. Oatly's latest growth shows that a branded alternative-protein company can build a substantial business.

The key question is what the startup uniquely brings. A strong strain, protein, fermentation process, formulation or recognizable consumer brand can justify an independent company. Owning a mediocre product plus an expensive factory and a large marketing budget is much harder to defend.

As capital has tightened, the old ambition to control the entire chain from biology to factory to supermarket shelf looks less attractive. Specialization is winning more often.

Is alternative protein still a good venture-capital market?

Alternative protein is still investable, but only a narrower group of business models currently makes sense for venture capital.

The latest funding data make the reset impossible to miss. GFI estimates that alternative protein companies raised $881 million in 2025 and another $359 million in the first half of 2026. Since 2017 the sector has raised more than $19.5 billion, so today's annual funding pace sits far below the boom years.

The composition is interesting. Plant-based companies raised $450 million in 2025, fermentation companies $357 million and cultivated meat companies about $74 million. At least 19 plant-based companies were acquired during the year. In cultivated meat, several companies merged, sold assets or stopped operating altogether.

Venture capital therefore appears to be moving toward companies where technology can create leverage. A proprietary protein sold across many food brands can scale without spending heavily to build consumer awareness for every product. A fermentation platform can serve multiple molecules. A CDMO can manufacture for many customers. An ingredient with real intellectual property can potentially earn margins that a normal packaged-food company cannot.

A plant-based burger company deserves a different valuation framework. If it owns limited proprietary technology, spends heavily on marketing and produces food at ordinary food-industry margins, then economically it is a food business. There is nothing wrong with that, but a food business cannot justify software-like valuation assumptions indefinitely.

The market has become much more rational on this point lately. Investors are asking less often whether the technology could transform a trillion-dollar food system and more often whether one company can actually capture enough of that value.

What business models actually work in the alternative protein market?

The alternative protein business models working best today are habitual plant-based foods, established fermentation products and increasingly B2B functional ingredients; capital-heavy attempts to replace conventional meat one-for-one remain much weaker.

Plant-based milk gives us the clearest mass-market example. Consumers already buy it frequently, the category owns a meaningful share of conventional milk, and a scaled company such as Oatly can now produce gross margins above 30%. Tofu, tempeh and Quorn show another route: products can build durable businesses without perfectly reproducing animal meat.

The most interesting newer model is precision-fermented ingredients. EVERY's recent order growth, commercial manufacturing partnerships around proteins such as beta-lactoglobulin, Perfect Day's work with major food companies and the expansion of dedicated fermentation CDMOs all point in the same direction. The business gets stronger when the startup owns a valuable molecule or process while somebody else supplies much of the expensive manufacturing and distribution infrastructure.

Cultivated meat remains the least proven large business model. Regulatory approvals are accumulating and real products have reached consumers, yet industry financing has collapsed from its peak and several well-funded producers have shut down. Hybrid products using cultivated fat or small amounts of cultivated material have a much more believable path today because they reduce the amount of expensive cell-culture output required per product.

The manufacturing lesson cuts across almost every segment. Capacity should follow demand. Companies that reverse that sequence can destroy enormous amounts of capital even when the underlying science works.

The alternative protein market is therefore splitting into very different businesses. Some already look like normal food companies. Some increasingly resemble specialty ingredient or industrial-biotech companies. Others are still expensive technology experiments searching for an economic model.

That separation gives us a much clearer answer than asking whether “alternative protein” as a whole works.

Business model	Evidence today	Capital intensity	Our judgment
Plant-based milk and other habitual plant foods	Large recurring consumer base, meaningful category share	Low to moderate	Proven
Tofu, tempeh and established mycoprotein	Long-standing demand and simpler consumer proposition	Moderate	Proven
Branded plant-based meat analogs	Real core consumers but shrinking penetration and weak specialist economics	Moderate to high	Weak today
B2B precision-fermented functional proteins	Growing commercial orders, major partnerships and capacity expansion	Moderate when outsourced	Strongest emerging model
Precision-fermentation CDMO	Real contracted demand beginning to appear	High	Promising if utilization stays high
Hybrid cultivated products and cultivated fat	Regulatory approvals and early commercial sales	High	Plausible early model, still unproven at scale
Fully integrated mass-market cultivated meat	Little commercial volume despite heavy historical funding	Extremely high	Unproven
Alternative-protein technology, IP and research tools	Can sell across multiple producers or adjacent industries	Low to moderate	Attractive where the IP is genuinely scarce

If you want more recent data on this point, please see our latest alternative protein market report.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.